ClinicalTrials.gg
RecruitingNCT03888924Updated Nov 29, 2024

Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

A Phase 2 interventional study of Bacille Calmette-Guerin vaccine and Placebo in Multiple Sclerosis, sponsored by S. Andrea Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by S. Andrea Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.

Planned enrollment
118th of 230
100 · median 115
Started
2019
with 16 others
Phase 2
33 of 289
2 open now
Primary completion
2026-07
later than 48 of 89 live
Registered
139th of 289
by date
Lead sponsor
8 of 289
S. Andrea Hospital

Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 118th largest by planned enrollment of the 230 interventional ones that give a count, is one of 17 that started in 2019, is one of 33 in phase 2, reaches primary completion later than 48 of the 89 other live ones, and was the 139th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in Multiple Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be addressed by translational research in this field: progressive MS and the "dream" of a world free of MS. As far as the latter is concerned, the investigators can hope to make the dream come true by understanding the etiology of the disease and hence design definitive cures. A more realistic and pragmatic perspective may be the prevention of the clinical onset of the disease, a research field that promises to become increasingly important as the integration of genetic data with endophenotypes, magnetic resonance imaging and other biomarkers ameliorates the ability to predict the development of the disease under clinical circumstance. Bacille Calmette-Guerin (BCG) vaccine has been tested with encouraging results in early MS and clinically isolated syndrome (CIS). The knowledge that disease-modifying therapies work best when used early in the demyelinating process raises the question about whether to try this approach - which is safe, cheap and handy - in individuals with radiologically isolated syndrome (RIS).

Radiologically isolated syndrome is a new entity, diagnosed when the unanticipated magnetic resonance imaging (MRI) finding of brain spatial dissemination of focal white matter (WM) lesions highly suggestive of MS occurs in subjects without symptoms of MS, and with normal neurological examinations. Conversion to clinically isolated syndromes (CIS) were described in 84% of RIS individuals with spinal cord lesions over a median time of 1.6 years from the date of the first MRI. Whether or not to treat this condition remains currently a clinical conundrum. Bacille Calmette-Guérin (BCG) vaccine may have these characteristics since it resulted beneficial in early MS and first demyelinating episodes. Being safe, cheap and handy, the investigators propose to investigate its use to prevent progression of the demyelinating process in radiologically isolated syndrome. An approach such as BCG vaccine seems appropriate as a front-line immunomodulatory approach for RIS people. In a pilot study BCG vaccine was safe and effective in reducing disease activity at MRI, and the risk of developing persistent T1-hypointense lesions ('black holes' -BH- expression of tissue damage) in subjects with MS.

Read the detailed description

Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. This notwithstanding, safety, quality of life and overtreatment remain elements of strong concern for the subjects. Safe and manageable therapies that can be used since the (biological) onset of the disease, without risk of overtreatment, are important unmet needs in MS.

Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be addressed by translational research in this field: progressive MS and the "dream" of a world free of MS. As far as the latter is concerned, the investigators can hope to make the dream come true by understanding the etiology of the disease and hence design definitive cures. Unfortunately this perspective is neither at hand, nor it can be taken for granted that the etiologic targets, once discovered, will be readily treatable.

A more realistic and pragmatic perspective may be the prevention of the clinical onset of the disease, a research field that promises to become increasingly important as the integration of genetic data with endophenotypes, magnetic resonance imaging and other biomarkers ameliorates the ability to predict the development of the disease under clinical circumstance.

Epidemiological data supporting vitamin D supplementation and smoking avoidance are candidate approaches for primary and secondary prevention of the disease. Among other interventions that may have characteristics compatible with those of a preventive treatment, Bacille Calmette-Guerin (BCG) vaccine has been tested with encouraging results in early MS and clinically isolated syndrome (CIS). The knowledge that disease-modifying therapies work best when used early in the demyelinating process raises the question about whether to try this approach - which is safe, cheap and handy - in individuals with radiologically isolated syndrome (RIS).

Radiologically isolated syndrome is a new entity, diagnosed when the unanticipated magnetic resonance imaging (MRI) finding of brain spatial dissemination of focal white matter (WM) lesions highly suggestive of MS occurs in subjects without symptoms of MS, and with normal neurological examinations. Approximately one-third and two-thirds of individuals experience respectively clinical onset and/or radiological progression over a mean follow-up of five years. However, predictors (male sex, age \< 37, spinal cord involvement) of higher risk of progression have been identified and conversion to clinically isolated syndromes (CIS) were described in 84% of RIS individuals with spinal cord lesions over a median time of 1.6 years from the date of the first MRI; the same predictors have recently been shown to precede evolution toward primary progressive MS. Whether or not to treat this condition remains currently a clinical conundrum.

Bacille Calmette-Guérin (BCG) vaccine may have these characteristics since it resulted beneficial in early MS and first demyelinating episodes. Being safe, cheap and handy, the investigators propose to explore its use to prevent progression of the demyelinating process in radiologically isolated syndrome.

An approach such as BCG vaccine seems appropriate as a front-line immunomodulatory approach for RIS people. This project is proposed in the context of the activity of the Center for Experimental Neurological Therapies (CENTERS - a special project by the Fondazione Italiana Sclerosi Multipla - FISM). CENTERS is especially dedicated to phase II trials of this nature (independent, repurposing studies, that may be only funded by not-for-profit institutions).

1.2 Preliminary Results

Experimental and epidemiological evidences suggested benefit of exposure to microbial products (in the absence of infection, as is the case of vaccinations) in autoimmunity, including MS. In a pilot study BCG vaccine was safe and effective in reducing disease activity at MRI, and the risk of developing persistent T1-hypointense lesions ('black holes' -BH- expression of tissue damage) in subjects with MS. A placebo-controlled trial in people with clinically isolated syndrome supported the findings of the pilot study. The researchers observed benefit on disease activity at MRI, reduced development of BH, benefit on conversion to clinically definite MS over 5 years, during which the subjects took interferon beta beginning from six months after BCG or placebo.

The investigators consider timely an extension of the adjuvant approach to subjects with RIS, also considering recent achievements in 'metrics' suitable to analyze this condition: neuroimaging has recently allowed to improve the characterization of RIS (including the identification of individuals at higher risk of progression to MS; and to disclose cortical lesions and axonal damage in RIS brain; immune-metabolic profiling provides a complex correlation between immunometabolic cellular variables, that seems especially apt to analyze preclinical phase of neuroinflammation and to study an approach whose underlying mechanisms of actions remain largely unknown, in spite of encouraging clinical results.

1.3 Scientific rationale and main objectives

BCG vaccine showed beneficial effects on disease activity and possibly on tissue damage in relapsing-remitting MS and clinically isolated syndrome. The investigators now propose to evaluate whether and how BCG vaccine exerts favorable biological effects in individuals with RIS.

At present it is unclear whether the neuroprotective/neurorepair potential of BCG is a consequence of its ability to reduce central nervous system (CNS) inflammation or it depends on additional and specific mechanisms. Notably, neuroprotection after BCG vaccination was reported in models of Parkinson disease, suggesting a neuroprotective vaccine paradigm in which general (nonself-reactive) immune stimulation in the periphery can limit potentially deleterious microglial responses to a neuronal insult. Accordingly, convergent evidences suggest a role of BCG, as tumor necrosis factor (TNF)-inducer, in another immune-mediated disease, type I diabetes: TNF receptor 2 may mediate, at least in part, beneficial effects of BCG in neuroinflammation and type 1 diabetes by favoring apoptosis of autoreactive T cells, counteracting T cell regulatory deficit and last, but not least, fostering tissue repair.

Metabolic abnormalities suggestive of axonal damage were reported in a substantial proportion of RIS subjects and cortical lesions of fronto-temporal lobes were associated with predictors of evolution to multiple sclerosis (MS), such as spinal cord involvement, presence of oligoclonal bands on cerebrospinal fluid and dissemination in time on brain MRI. The researchers aim at verifying potential beneficial effects of BCG vaccination in people with RIS, evaluating MRI metrics of macroscopic brain damage, as well as subtle tissue damage as assessed by both conventional and non conventional MRI techniques. On the immunological side the investigators will assess the immune-metabolic status of RIS people as well as their regulatory T cell potential: a multiple parameter analysis will provide a meta-immunologic profiling that has been recently shown to be impaired in MS. This will be aimed at creating a follow-up scheme which should allow to monitor RIS people over time, before and after BCG vaccine.

To reach the above purposes the investigators propose a 3 years longitudinal study project, considered appropriate taking into account the relative rarity of RIS condition as well as the need of an adequate follow-up to obtain informative outcome measures (see methods).

The groups that engendered the above achievements are collaborators of this project, thus warranting the experience and competence to pursue the proposed research.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • BCG Vaccine
  • Radiologically Isolated Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female of any race and > 18 years old.
  2. Diagnosis of RIS (4) within the last five years.
  3. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Concomitant or previous use of or immunomodulating treatment (except sporadic use of ) within the last five years.
  3. Subjects with a or unstable medical or surgical condition that would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, severe systemic mycotic infections, metabolic diseases or , primary or secondary immunodeficiencies as determined by medical history, physical exam, laboratory tests, chest X-ray, (ECG), and Mantoux reaction.
  4. Any medical or psychiatric condition that may affect the subjects ability to give , or to complete the study, or if the subject is considered by the treating neurologist to be, for any other reason, an unsuitable candidate for this study.
  5. Subjects with inability to successfully undergo MRI scans.
  6. Concomitant radiotherapy.
  7. Known to any component of the vaccine.
  8. Past bone marrow stem cell transplantation and organ transplantation.
  9. Other vaccinations in the previous 4 weeks.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    BCG treated patients

    a single dose of Bacille Calmette-Guerin vaccine

    Drug: Bacille Calmette-Guerin vaccine

  • Placebo comparator
    Placebo treated patients

    a single dose of placebo.

    Drug: Placebo

Interventions

  • DrugBacille Calmette-Guerin vaccine

    One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain. One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain. Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride.

    Also known as: BCG 10 Anti-Tuberculosis Vaccine

  • DrugPlacebo

    isotonic solution of sodium chloride (2mL vials).

06

What researchers measure

Primary outcomes

  1. cumulative number of CUAL (new gadolinium T1-weighted lesions and non-enhancing new and newly enlarging T2-weighted lesions) on MRI scans over 1 year.

    To evaluate the cumulative number of new combined unique active lesions (CUAL; defined as new gadolinium T1-weighted lesions and non-enhancing new and newly enlarging T2-weighted lesions) on magnetic resonance imaging (MRI) scans over 1 year. Brain MRI will be acquired in all subjects at each centre using a magnet at 1.5T or 3T. * A sagittal survey image will be used to identify the anterior and posterior commissure (AC and PC). * A dual-echo, turbo spin-echo sequence (slice thickness: 3mm). * A high-resolution (3D, MPRAGE) T1- weighted image (slice thickness: 1mm). * A Magnetization Transfer (MT) sequence will be performed acquiring two 2-dimensional gradient-echo sequences, one without and one with MT saturation pulse (slice thickness: 3 mm). * A double inversion recovery (DIR) sequence * A T1-weighted scan, post-gadolinium injection, after 10-minute wait period. * A FLAIR sequence to be acquired between the DIR and the T1-weighted scans, after the gadolinium injection.

    Time frame: 12 months

Secondary outcomes

  1. Time to the first clinical event.

    The secondary endpoint will be the time to the first clinical event over the 3 years period. Five visits (including physical and neurological examinations) per subject are planned: * Visit 1 - from day -3 to day +1 * Visit 2 - 6 months (±7 days) * Visit 3 - 12 months (±7 days) * Visit 4 - 24 months (±7 days) * Visit 5 - 36 months (±7 days)

    Time frame: 36 months

Other outcomes

  1. number of cortical lesions

    To evaluate the number of cortical lesions on magnetic resonance imaging (MRI) scans at 6 months, as well as at 1, 2 and 3 years: Cortical lesions will be assessed on the DIR sequence and defined as those focal hyperintensities entirely or partly located in the cortical GM.

    Time frame: 6, 12, 24, 36 months

  2. Percentage of Brain Volume Changes (PBVC)

    Brain atrophy (global and regional) will be assessed on the 3D T1-weighted images using the software SIENA/SIENAX (Structural Image Evaluation, using Normalization, of Atrophy) method.

    Time frame: 6, 12, 24, 36 months

  3. Cortical and white matter Volume Changes

    Brain atrophy (global and regional) will be assessed on the 3D T1-weighted images using the software SIENA/SIENAX (Structural Image Evaluation, using Normalization, of Atrophy) method. To avoid GM misclassification due to WM lesions, the latter will be masked out and refilled with intensities matching the surrounding normal-appearing WM before segmentation analysis. Volume in the subcortical grey matter will be assessed with FMRIB's Integrated Registration and Segmentation Tool (FIRST).

    Time frame: 6, 12, 24, 36 months

  4. Magnetization Transfer ratio (MTr) in lesions

    Magnetization Transfer (MT) sequence will be performed acquiring two 2-dimensional gradient-echo sequences, one without and one with MT saturation pulse, which allows to obtain MT ratio in lesions, and normal-appearing brain.

    Time frame: 6, 12, 24, 36 months

  5. Magnetization Transfer ratio (MTr) in normal-appearing brain

    Magnetization Transfer (MT) sequence will be performed acquiring two 2-dimensional gradient-echo sequences, one without and one with MT saturation pulse, which allows to obtain MT ratio in lesions, and normal-appearing brain.

    Time frame: 6, 12, 24, 36 months

07

Study locations

1 of 1 sites recruiting
  • Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome
    Rome, 00139, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Jul 2026, 84 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 84 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2018
First posted
Mar 25, 2019
StartActual
Jun 17, 2019
Primary completionEst.
Jul 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03888924
Lead sponsor
S. Andrea Hospital
Responsible party
Giovanni Ristori (Medical director, PhD, S. Andrea Hospital) — Principal investigator
First posted
Mar 25, 2019
Start date
Jun 17, 2019
Primary completion
Jul 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Nov 29, 2024

Study contacts

Giovanni Ristori, MD
Contact
giovanni.ristori@uniroma1.it
+390633776044 ext. 6044
Giovanni Ristori
principal investigator · S.Andrea Hospital, University of Roma La Sapienza

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion